2011
Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy
Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, Fuchs D, Palmer S, Price RW. Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy. The Journal Of Infectious Diseases 2011, 204: 1936-1945. PMID: 22021620, PMCID: PMC3209817, DOI: 10.1093/infdis/jir667.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsHIV-1 RNAImmune activationRaltegravir intensificationRNA levelsPlasma human immunodeficiency virus type 1 (HIV-1) RNACSF HIV-1 RNA levelsMedian HIV-1 RNA levelT-cell surface antigen expressionHuman immunodeficiency virus type 1 (HIV-1) RNAOpen-label pilot studySingle-copy assayHIV RNA levelsCerebrospinal fluid infectionHIV-1 infectionCentral nervous systemBaseline viral suppressionSurface antigen expressionT cell activationCSF neopterinIntrathecal immunoactivationSuppressive therapyAntiretroviral therapyTreatment intensificationViral suppression
2010
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection
Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, Price RW, Fuchs D. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Research And Therapy 2010, 7: 15. PMID: 20525234, PMCID: PMC2890504, DOI: 10.1186/1742-6405-7-15.Peer-Reviewed Original ResearchCSF HIV RNACSF neopterin concentrationsCSF neopterinCentral nervous systemIntrathecal immunoactivationCNS infectionsHIV RNANeopterin concentrationsImmune activationCerebrospinal fluidCentral nervous system immune activationNeurological diseasesBlood CD4 cell countCNS HIV infectionIntrathecal immune activationOngoing brain injuryOpportunistic CNS infectionsCD4 cell countCombination antiretroviral therapyCNS opportunistic infectionsMacrophage activation markersHIV-1 infectionSuppression of plasmaUntreated AIDS patientsAbsence of treatment
2008
Failure of atorvastatin to modulate CSF HIV-1 infection
Probasco JC, Spudich SS, Critchfield J, Lee E, Lollo N, Deeks SG, Price RW. Failure of atorvastatin to modulate CSF HIV-1 infection. Neurology 2008, 71: 521-524. PMID: 18695163, PMCID: PMC2676982, DOI: 10.1212/01.wnl.0000325006.84658.e7.Peer-Reviewed Original ResearchConceptsHIV-1 infectionHIV-1 RNA levelsT-cell countsCell countIntrathecal immunoactivationNeopterin concentrationsBlood lipidsBlood HIV-1 RNA levelCSF HIV-1 RNA levelsCSF white blood cell countCNS HIV-1 infectionSystemic HIV-1 infectionSingle-arm pilot studyWhite blood cell countPilot studyAntiretroviral-naïve subjectsCells/mulRNA levelsUntreated systemic infectionT-lymphocyte countsSmall uncontrolled studiesEffect of atorvastatinHMG-CoA reductase inhibitorsWeeks of treatmentHIV-1 RNA
2007
Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy
Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. The Journal Of Infectious Diseases 2007, 196: 1779-1783. PMID: 18190258, DOI: 10.1086/523648.Peer-Reviewed Original ResearchConceptsHIV RNA levelsCopies/mLActive antiretroviral therapyIntrathecal immunoactivationNeopterin levelsCerebrospinal fluidIgG indexAntiretroviral therapyPlasma HIV RNA levelsMacrophage/microglia activationHuman immunodeficiency virus (HIV) RNAUpper normal reference valueIntrathecal immunoglobulin productionYears of treatmentCentral nervous systemNormal reference valuesMicroglia activationImmune activationImmunoglobulin productionEffective treatmentCSF samplesPatientsNervous systemCell countHAART
2006
Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers
Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers. Journal Of Neuroimmune Pharmacology 2006, 2: 112-119. PMID: 18040834, DOI: 10.1007/s11481-006-9035-1.Peer-Reviewed Original ResearchConceptsCNS HIV infectionAIDS dementia complexHIV infectionBrain injuryTreatment targetsCentral nervous system infectionNeurodegenerative diseasesSystemic HIV infectionComorbidities of patientsNervous system infectionAdjuvant treatment approachesCerebrospinal fluid markersRational trial designIntrathecal immunoactivationSystem infectionDementia complexAvailable treatmentsClinical trialsFluid markersTrial designTreatment approachesClinical practiceExperimental therapeuticsPatientsInfection